BACKGROUND: Neuroblastoma is a biologically and clinically heterogeneous disease. Based on recent studies demonstrating an association between the primary tumor site, prognosis, and commonly measured tumor biological features, we hypothesized that neuroblastomas arising in different sites would show distinct genomic features reflective of the developmental biology of the sympathicoadrenal nervous system. METHODS: We first compared genomic and epigenomic data of primary diagnostic neuroblastomas originating in the adrenal gland (n = 646) compared to thoracic sympathetic ganglia (n = 118). We also evaluated association of common germline variation with these primary sites in 1027 European-American neuroblastoma patients. RESULTS: We observed higher rates of MYCN amplification, chromosome 1q gain, and chromosome 11q deletion among adrenal tumors, which were highly predictive of functional RNA signatures. Surprisingly, thoracic neuroblastomas were more likely to harbor ALK driver mutations than adrenal cases among all cases (odds ratio = 1.89, 95% confidence interval = 1.04 to 3.43), and among cases without MYCN amplification (odds ratio = 2.86, 95% confidence interval = 1.48 to 5.49). Common germline single nucleotide polymorphisms (SNPs) in BARD1 (previously associated with high-risk neuroblastoma) were found to be strongly associated with predisposition for origin at adrenal, rather than thoracic, sites. CONCLUSIONS: Neuroblastomas arising in the adrenal gland are more likely to harbor structural DNA aberrations including MYCN amplification, whereas thoracic tumors show defects in mitotic checkpoints resulting in hyperdiploidy. Despite the general association of ALK mutations with high-risk disease, thoracic tumors are more likely to harbor gain-of-function ALK aberrations. Site of origin is likely reflective of stage of sympathetic nervous system development when malignant transformation occurs and is a surrogate for underlying tumor biology.
BACKGROUND:Neuroblastoma is a biologically and clinically heterogeneous disease. Based on recent studies demonstrating an association between the primary tumor site, prognosis, and commonly measured tumor biological features, we hypothesized that neuroblastomas arising in different sites would show distinct genomic features reflective of the developmental biology of the sympathicoadrenal nervous system. METHODS: We first compared genomic and epigenomic data of primary diagnostic neuroblastomas originating in the adrenal gland (n = 646) compared to thoracic sympathetic ganglia (n = 118). We also evaluated association of common germline variation with these primary sites in 1027 European-American neuroblastomapatients. RESULTS: We observed higher rates of MYCN amplification, chromosome 1q gain, and chromosome 11q deletion among adrenal tumors, which were highly predictive of functional RNA signatures. Surprisingly, thoracic neuroblastomas were more likely to harbor ALK driver mutations than adrenal cases among all cases (odds ratio = 1.89, 95% confidence interval = 1.04 to 3.43), and among cases without MYCN amplification (odds ratio = 2.86, 95% confidence interval = 1.48 to 5.49). Common germline single nucleotide polymorphisms (SNPs) in BARD1 (previously associated with high-risk neuroblastoma) were found to be strongly associated with predisposition for origin at adrenal, rather than thoracic, sites. CONCLUSIONS:Neuroblastomas arising in the adrenal gland are more likely to harbor structural DNA aberrations including MYCN amplification, whereas thoracic tumors show defects in mitotic checkpoints resulting in hyperdiploidy. Despite the general association of ALK mutations with high-risk disease, thoracic tumors are more likely to harbor gain-of-function ALK aberrations. Site of origin is likely reflective of stage of sympathetic nervous system development when malignant transformation occurs and is a surrogate for underlying tumor biology.
Authors: Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman Journal: J Clin Oncol Date: 2010-04-19 Impact factor: 44.544
Authors: Lukas C Heukamp; Theresa Thor; Alexander Schramm; Katleen De Preter; Candy Kumps; Bram De Wilde; Andrea Odersky; Martin Peifer; Sven Lindner; Annika Spruessel; Filip Pattyn; Pieter Mestdagh; Björn Menten; Steffi Kuhfittig-Kulle; Annette Künkele; Katharina König; Lydia Meder; Sampurna Chatterjee; Roland T Ullrich; Stefanie Schulte; Jo Vandesompele; Frank Speleman; Reinhard Büttner; Angelika Eggert; Johannes H Schulte Journal: Sci Transl Med Date: 2012-07-04 Impact factor: 17.956
Authors: Eric A Hungate; Mark A Applebaum; Andrew D Skol; Zalman Vaksman; Maura Diamond; Lee McDaniel; Samuel L Volchenboum; Barbara E Stranger; John M Maris; Sharon J Diskin; Kenan Onel; Susan L Cohn Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506
Authors: Daria Thompson; Kieuhoa T Vo; Wendy B London; Matthias Fischer; Peter F Ambros; Akira Nakagawara; Garrett M Brodeur; Katherine K Matthay; Steven G DuBois Journal: Cancer Date: 2015-12-28 Impact factor: 6.860
Authors: Yaël P Mossé; Marci Laudenslager; Luca Longo; Kristina A Cole; Andrew Wood; Edward F Attiyeh; Michael J Laquaglia; Rachel Sennett; Jill E Lynch; Patrizia Perri; Geneviève Laureys; Frank Speleman; Cecilia Kim; Cuiping Hou; Hakon Hakonarson; Ali Torkamani; Nicholas J Schork; Garrett M Brodeur; Gian P Tonini; Eric Rappaport; Marcella Devoto; John M Maris Journal: Nature Date: 2008-08-24 Impact factor: 49.962
Authors: G Schleiermacher; V Mosseri; W B London; J M Maris; G M Brodeur; E Attiyeh; M Haber; J Khan; A Nakagawara; F Speleman; R Noguera; G P Tonini; M Fischer; I Ambros; T Monclair; K K Matthay; P Ambros; S L Cohn; A D J Pearson Journal: Br J Cancer Date: 2012-09-13 Impact factor: 7.640
Authors: Vid Mlakar; Simona Jurkovic Mlakar; Gonzalo Lopez; John M Maris; Marc Ansari; Fabienne Gumy-Pause Journal: Mol Cancer Date: 2017-06-29 Impact factor: 27.401
Authors: Rani E George; Takaomi Sanda; Megan Hanna; Stefan Fröhling; William Luther; Jianming Zhang; Yebin Ahn; Wenjun Zhou; Wendy B London; Patrick McGrady; Liquan Xue; Sergey Zozulya; Vlad E Gregor; Thomas R Webb; Nathanael S Gray; D Gary Gilliland; Lisa Diller; Heidi Greulich; Stephan W Morris; Matthew Meyerson; A Thomas Look Journal: Nature Date: 2008-10-16 Impact factor: 49.962
Authors: Kevin Campbell; Arlene Naranjo; Emily Hibbitts; Julie M Gastier-Foster; Rochelle Bagatell; Meredith S Irwin; Hiroyuki Shimada; Michael Hogarty; Julie R Park; Steven G DuBois Journal: Eur J Cancer Date: 2020-05-31 Impact factor: 9.162
Authors: Andrea K Watters; Emily S Seltzer; Danny MacKenzie; Melody Young; Jonathan Muratori; Rama Hussein; Andrej M Sodoma; Julie To; Manrose Singh; Dong Zhang Journal: Genes (Basel) Date: 2020-07-21 Impact factor: 4.096
Authors: Jian-Guo Zhou; Bo Liang; Su-Han Jin; Hui-Ling Liao; Guo-Bo Du; Long Cheng; Hu Ma; Udo S Gaipl Journal: Front Oncol Date: 2019-12-04 Impact factor: 6.244